Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

NICE Endorses Cabozantinib Plus Nivolumab in Advanced RCC

April 2nd 2024

NICE has recommended the combination of cabozantinib and nivolumab for adult patients with advanced renal cell carcinoma in a final draft guidance.

Durvalumab Plus Guadecitabine Shows PFS Benefit in Cohort of Patients With ccRCC

April 1st 2024

Durvalumab in combination with guadecitabine was tolerable and led to a PFS benefit in patients with checkpoint inhibitor-naive ccRCC.

Ongoing Trials Aim to Build on Systemic Therapy Combinations in Advanced RCC

April 1st 2024

Wenxin (Vincent) Xu, MD, shares recent updates in the treatment of renal cell carcinoma, including insights into ongoing research and trials within the space.

Key Takeaways on Updates in Bladder Cancer

April 1st 2024

Elizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.

Establishing Biomarkers Is Key to Driving Personalized Systemic Treatment Choices in Advanced RCC

March 30th 2024

Wenxin (Vincent) Xu, MD, discusses the evolving landscape of systemic therapy in RCC, sharing how he makes treatment decisions amid the changing treatment space.

Dr Bilusic on the Non-ccRCC Treatment Armamentarium

March 29th 2024

Marijo Bilusic, MD, PhD, discusses combination regimens under investigation for patients with non–clear cell renal cell carcinoma.

Updates on LITESPARK-005 and LITESPARK-011 in Advanced RCC

March 29th 2024

Focusing on belzutifan, Laurence Albigès, MD, PhD, reviews data from the LITESPARK-005 clinical trial, and Martin H. Voss, MD, discusses the ongoing LITESPARK-011 trial.

CONTACT-03: Atezolizumab Plus Cabozantinib in Advanced RCC

March 29th 2024

Experts on advanced RCC discuss the CONTACT-03 trial evaluating atezolizumab plus cabozantinib following immune checkpoint inhibitor treatment in patients with inoperable disease.

Dr Merchán on the Role of Immunotherapy and TKI Combinations in RCC

March 28th 2024

Jaime R. Merchán, MD, discusses the current roles for immunotherapy and TKIs in patients with renal cell carcinoma.

Dr Xu on Ongoing Research Initiatives in ccRCC

March 27th 2024

Wenxin (Vincent) Xu, MD, highlights research in renal cell carcinoma, spotlighting developments and updates in patients with non-clear cell disease.

Dr Xu on Changes in Systemic Therapy in RCC

March 26th 2024

Wenxin (Vincent) Xu, MD, on evolving systemic therapy and the utilization of biomarkers in the treatment of renal cell carcinoma.

Exciting New Approaches in Metastatic Urothelial Carcinoma

March 25th 2024

Experts on bladder cancer discuss exciting new agents and treatment strategies and where they can potentially fit into urothelial cancer treatment paradigms.

Treatment Sequencing Practices in Metastatic Urothelial Carcinoma

March 25th 2024

Focusing on metastatic urothelial carcinoma, the panel discusses the role of chemotherapy and outlines treatment sequencing approaches.

Dr Xu on Treatment Decision-Making in RCC

March 22nd 2024

Wenxin (Vincent) Xu, MD, discusses treatment decision-making in patients with renal cell carcinoma.

Treatment Decisions in the Second Line and Beyond in Advanced Clear Cell RCC

March 22nd 2024

David A. Braun, MD, PhD, provides clinical insights on factors that influence treatment decisions in the second line and beyond for patients with advanced clear cell RCC.

LITESPARK-003 and LITESPARK-024: Ongoing Belzutifan Research

March 22nd 2024

Focusing on the LITESPARK-003 and LITESPARK-024 trials, Laurence Albigès, MD, PhD, discusses novel doublet regimens under investigation in the first-line setting in advanced renal cell carcinoma.

Later-Line Therapies for Metastatic Urothelial Carcinoma

March 18th 2024

Evan Y. Yu, MD, provides insights on treatment approaches for patients with metastatic urothelial carcinoma in the second line and beyond.

Cisplatin Eligibility and Maintenance Therapy in Metastatic Urothelial Carcinoma

March 18th 2024

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

Dr Liu on Surgical Outcomes Following Radiation and Chemotherapy in Rectal Cancer

March 16th 2024

I-Chia (Daniel) Liu, MD, discusses surgical and local control outcomes following short-course radiation therapy and chemotherapy for rectal cancer.

Clinical Pearls for Managing IO-TKI and IO-IO Toxicity in Advanced RCC

March 15th 2024

Medical oncologists provide clinical insights on managing adverse events associated with IO-TKI and IO-IO regimens in patients with advanced renal cell carcinoma.